Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CRSP
CRSP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CRSP News
CRISPR Therapeutics: A Biotech Stock Poised for Growth
1d ago
Fool
CRISPR Therapeutics Shows Growth Potential
1d ago
NASDAQ.COM
CRISPR Therapeutics Stock Rises Despite Poor Q4 Earnings
1d ago
Fool
Casgevy Therapy Revenue Shows Significant Growth
1d ago
Benzinga
CRISPR Therapeutics Reports Q4 Losses Amid Revenue Decline
2d ago
seekingalpha
Cathie Wood's Investment Outlook for 2026
Jan 30 2026
Fool
CRISPR Therapeutics: A Promising Biotech Investment
Jan 29 2026
Fool
Wall Street Focuses on Earnings and Commodity Prices
Jan 29 2026
stocktwits
CRISPR Therapeutics Faces Renewed Pressure Amid Insider Sales
Jan 27 2026
Benzinga
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
Jan 21 2026
Benzinga
Ark Invest Unveils 2026 Big Ideas, Focus on AI and Genomics
Jan 20 2026
Benzinga
CRISPR Therapeutics (CRSP) Options Trading Volume Hits 9,323 Contracts, 57.4% of Average Daily Volume
Jan 12 2026
NASDAQ.COM
CRISPR Therapeutics and Summit Therapeutics: Investment Outlook for 2026
Jan 12 2026
Fool
CRISPR Therapeutics Outlines Strategic Priorities and Milestones for 2026
Jan 12 2026
Globenewswire
CRISPR Therapeutics Outlines 2026 Strategy and Milestones with $2 Billion Cash Position
Jan 12 2026
Newsfilter
HUTCHMED Reports Phase 3 Data for Sovleplenib, Plans NDA Submission in 2026
Jan 07 2026
Benzinga
Show More News
